RU2015142981A3 - - Google Patents
Download PDFInfo
- Publication number
- RU2015142981A3 RU2015142981A3 RU2015142981A RU2015142981A RU2015142981A3 RU 2015142981 A3 RU2015142981 A3 RU 2015142981A3 RU 2015142981 A RU2015142981 A RU 2015142981A RU 2015142981 A RU2015142981 A RU 2015142981A RU 2015142981 A3 RU2015142981 A3 RU 2015142981A3
- Authority
- RU
- Russia
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/08—RNA viruses
- C07K14/115—Paramyxoviridae, e.g. parainfluenza virus
- C07K14/135—Respiratory syncytial virus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/543—Mucosal route intranasal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/22—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a Strep-tag
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/50—Fusion polypeptide containing protease site
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/735—Fusion polypeptide containing domain for protein-protein interaction containing a domain for self-assembly, e.g. a viral coat protein (includes phage display)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
- C12N2760/18522—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
- C12N2760/18523—Virus like particles [VLP]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
- C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Genetics & Genomics (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Pulmonology (AREA)
- Urology & Nephrology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361780910P | 2013-03-13 | 2013-03-13 | |
| US61/780,910 | 2013-03-13 | ||
| US201361798389P | 2013-03-15 | 2013-03-15 | |
| US61/798,389 | 2013-03-15 | ||
| US201361857613P | 2013-07-23 | 2013-07-23 | |
| US61/857,613 | 2013-07-23 | ||
| US201361863909P | 2013-08-09 | 2013-08-09 | |
| US61/863,909 | 2013-08-09 | ||
| PCT/US2014/026714 WO2014160463A1 (en) | 2013-03-13 | 2014-03-13 | Prefusion rsv f proteins and their use |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2021132097A Division RU2852571C2 (ru) | 2013-03-13 | 2014-03-13 | Белки rsv f в предшествующей слиянию конформации и их применение |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| RU2015142981A RU2015142981A (ru) | 2017-04-17 |
| RU2015142981A3 true RU2015142981A3 (enExample) | 2018-03-14 |
| RU2761631C2 RU2761631C2 (ru) | 2021-12-13 |
Family
ID=51625430
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2015142981A RU2761631C2 (ru) | 2013-03-13 | 2014-03-13 | Белки rsv в предшествующей слиянию конформации и их применение |
Country Status (21)
| Country | Link |
|---|---|
| US (5) | US10017543B2 (enExample) |
| EP (2) | EP4421177A3 (enExample) |
| JP (4) | JP6703475B2 (enExample) |
| KR (3) | KR102766946B1 (enExample) |
| CN (2) | CN105473604B (enExample) |
| AU (5) | AU2014243756B2 (enExample) |
| CA (1) | CA2902877A1 (enExample) |
| DK (1) | DK2970398T3 (enExample) |
| ES (1) | ES2981623T3 (enExample) |
| FI (1) | FI2970398T3 (enExample) |
| HR (1) | HRP20240996T1 (enExample) |
| HU (1) | HUE067333T2 (enExample) |
| LT (1) | LT2970398T (enExample) |
| MX (2) | MX385818B (enExample) |
| PL (1) | PL2970398T3 (enExample) |
| PT (1) | PT2970398T (enExample) |
| RS (1) | RS65760B1 (enExample) |
| RU (1) | RU2761631C2 (enExample) |
| SI (1) | SI2970398T1 (enExample) |
| SM (1) | SMT202400297T1 (enExample) |
| WO (1) | WO2014160463A1 (enExample) |
Families Citing this family (150)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20080124355A1 (en) | 2006-09-22 | 2008-05-29 | David Gordon Bermudes | Live bacterial vaccines for viral infection prophylaxis or treatment |
| US20110229471A1 (en) | 2008-11-26 | 2011-09-22 | Cedars-Sinai Medical Center | Methods of determining responsiveness to anti-tnf alpha therapy in inflammatory bowel disease |
| WO2012116715A1 (en) | 2011-03-02 | 2012-09-07 | Curevac Gmbh | Vaccination in newborns and infants |
| DK2950886T3 (da) | 2013-02-01 | 2020-03-23 | Medimmune Llc | Respiratorisk syncytialvirus-f-protein-epitoper |
| SMT202400297T1 (it) | 2013-03-13 | 2024-09-16 | The United States Of America As Represented By The Secretary Department Of Health And Human Services | Proteine f del rsv pre-fusione e loro uso |
| US9738689B2 (en) | 2013-03-13 | 2017-08-22 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Prefusion RSV F proteins and their use |
| AU2014239583B2 (en) | 2013-03-14 | 2020-07-02 | Children's Healthcare Of Atlanta, Inc. | Recombinant RSV with silent mutations, vaccines, and methods related thereto |
| EP3639841B1 (en) | 2013-03-27 | 2023-09-06 | Cedars-Sinai Medical Center | Treating fibrosis by inhibiting tl1a |
| SG11201508567XA (en) | 2013-04-25 | 2015-11-27 | Crucell Holland Bv | Stabilized soluble prefusion rsv f polypeptides |
| CN105408348B (zh) | 2013-06-17 | 2021-07-06 | 扬森疫苗与预防公司 | 稳定化的可溶性融合前rsv f多肽 |
| EP3022295A4 (en) | 2013-07-19 | 2017-03-01 | Cedars-Sinai Medical Center | Signature of tl1a (tnfsf15) signaling pathway |
| EP3024483B1 (en) | 2013-07-25 | 2020-01-15 | Calder Biosciences Inc. | Conformationally stabilized rsv pre-fusion f proteins |
| ES2747762T3 (es) | 2013-08-21 | 2020-03-11 | Curevac Ag | Vacuna contra el virus respiratorio sincitial (RSV) |
| CA2925201A1 (en) * | 2013-09-24 | 2015-04-02 | Massachusetts Institute Of Technology | Self-assembled nanoparticle vaccines |
| US9630994B2 (en) | 2014-11-03 | 2017-04-25 | University Of Washington | Polypeptides for use in self-assembling protein nanostructures |
| CA2974359A1 (en) | 2015-01-20 | 2016-07-28 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Recombinant parainfluenza virus expressing a chimeric f protein and uses thereof |
| EP3250233A4 (en) | 2015-01-29 | 2018-07-25 | Agency for Science, Technology and Research | Nanocapsules carrying chikungunya-associated peptides |
| US10676723B2 (en) | 2015-05-11 | 2020-06-09 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
| EA039065B1 (ru) * | 2015-07-07 | 2021-11-29 | Янссен Вэксинс Энд Превеншн Б.В. | Вакцина против rsv |
| US10457708B2 (en) | 2015-07-07 | 2019-10-29 | Janssen Vaccines & Prevention B.V. | Stabilized soluble pre-fusion RSV F polypeptides |
| FR3041962B1 (fr) * | 2015-10-01 | 2018-01-05 | Lab Francais Du Fractionnement | Procede d'enrichissement d'une preparation d'immunoglobulines en immunoglobulines anti-rsv et preparation ainsi enrichie |
| KR20180096592A (ko) * | 2015-10-22 | 2018-08-29 | 모더나티엑스, 인크. | 호흡기 세포융합 바이러스 백신 |
| MA52645B1 (fr) | 2015-10-22 | 2022-06-30 | Modernatx Inc | Vaccins contre le virus respiratoire |
| WO2017075125A1 (en) | 2015-10-29 | 2017-05-04 | Emory University | Chimeric RSV, Immunogenic Compositions, and Methods of Use |
| PE20181354A1 (es) * | 2015-12-23 | 2018-08-22 | Pfizer | Mutantes de proteina f de rsv |
| JP7082945B2 (ja) | 2016-03-17 | 2022-06-09 | シーダーズ―シナイ メディカル センター | Ｒｎａｓｅｔ２により炎症性腸疾患を診断する方法 |
| CN109069611B (zh) * | 2016-03-29 | 2022-11-04 | 美国政府(由卫生和人类服务部的部长所代表) | 取代修饰的融合前rsv f蛋白及其用途 |
| EP3808374A1 (en) | 2016-04-05 | 2021-04-21 | Janssen Vaccines & Prevention B.V. | Stabilized soluble pre-fusion rsv f proteins for use in the prophylaxis of rsv infection |
| CN109069612A (zh) | 2016-04-05 | 2018-12-21 | 扬森疫苗与预防公司 | 针对rsv的疫苗 |
| IL245059A0 (en) | 2016-04-12 | 2016-06-30 | Technion Res & Dev Foundation | Electrospun scaffolds from extracellular matrix |
| PE20190110A1 (es) | 2016-05-30 | 2019-01-15 | Janssen Vaccines And Prevention B V | Proteinas f de prefusion del vrs estabilizadas |
| US10961283B2 (en) | 2016-06-27 | 2021-03-30 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Self-assembling insect ferritin nanoparticles for display of co-assembled trimeric antigens |
| CN106119287B (zh) * | 2016-08-29 | 2019-10-11 | 广东华南疫苗股份有限公司 | 一种表达呼吸道合胞病毒f蛋白的重组载体及方法 |
| EP3518967A4 (en) | 2016-10-03 | 2020-04-29 | University of Massachusetts | Methods for immunizing pre-immune subjects against respiratory syncytial virus (rsv) |
| EP3532096B1 (en) | 2016-10-25 | 2023-02-22 | The U.S.A. as represented by the Secretary, Department of Health and Human Services | Prefusion piv f immunogens and their use |
| SG11201903737PA (en) * | 2016-10-26 | 2019-05-30 | Cedars Sinai Medical Center | Neutralizing anti-tl1a monoclonal antibodies |
| TWI683826B (zh) * | 2016-11-22 | 2020-02-01 | 國立臺灣大學 | 重組ｒｓｖ抗原 |
| US11180535B1 (en) | 2016-12-07 | 2021-11-23 | David Gordon Bermudes | Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria |
| US11129906B1 (en) | 2016-12-07 | 2021-09-28 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
| MA50335A (fr) | 2016-12-08 | 2020-08-19 | Modernatx Inc | Vaccins à acide nucléique contre des virus respiratoires |
| CA3043790A1 (en) | 2016-12-16 | 2018-06-21 | Institute For Research In Biomedicine | Novel recombinant prefusion rsv f proteins and uses thereof |
| GB201621686D0 (en) | 2016-12-20 | 2017-02-01 | Glaxosmithkline Biologicals Sa | Novel methods for inducing an immune response |
| CN108265079A (zh) * | 2017-01-02 | 2018-07-10 | 刘昕 | 一种新型呼吸道合胞体病毒pre-F融合蛋白载体的制备方法 |
| EP3595713A4 (en) | 2017-03-15 | 2021-01-13 | ModernaTX, Inc. | Respiratory syncytial virus vaccine |
| WO2018175518A1 (en) * | 2017-03-22 | 2018-09-27 | The Scripps Research Institute | Mini-protein immunogens displayng neutralization epitopes for respiratory syncytial virus (rsv) |
| LT3606942T (lt) | 2017-04-04 | 2025-10-10 | Savaiminės sąrankos baltymų nanostruktūros, eksponuojančios paramiksoviruso ir (arba) pneumoviruso f baltymus ir jų naudojimas | |
| CA3061278A1 (en) | 2017-05-17 | 2018-11-22 | Janssen Vaccines & Prevention B.V. | Methods and compositions for inducing protective immunity against rsv infection |
| FR3066920A1 (fr) | 2017-05-30 | 2018-12-07 | Glaxosmithkline Biologicals S.A. | Nouveaux procedes de fabrication d'un adjuvant |
| MX2019014719A (es) * | 2017-06-14 | 2020-08-03 | Virometix Ag | Peptidos ciclicos para proteccion contra el virus sincitial respiratorio. |
| AU2018313000B2 (en) * | 2017-08-07 | 2025-07-03 | Calder Biosciences Inc. | Conformationally stabilized RSV pre-fusion F proteins |
| BR112020004143A2 (pt) | 2017-09-15 | 2020-09-01 | Janssen Vaccines & Prevention B.V. | método para a indução segura de imunidade contra vírus sincicial respiratório (rsv) |
| JP2019092481A (ja) * | 2017-11-27 | 2019-06-20 | 国立大学法人東京工業大学 | ヘテロタンパク質ケージ |
| WO2019106192A1 (en) | 2017-12-01 | 2019-06-06 | Glaxosmithkline Biologicals Sa | Saponin purification |
| BR112020015308A8 (pt) | 2018-01-29 | 2023-02-07 | Merck Sharp & Dohme | Proteínas f de rsv estabilizadas e usos das mesmas |
| US11911453B2 (en) * | 2018-01-29 | 2024-02-27 | Modernatx, Inc. | RSV RNA vaccines |
| AU2019228551B2 (en) | 2018-02-28 | 2025-07-24 | University Of Washington | Self-assembling nanostructure vaccines |
| WO2019178521A1 (en) * | 2018-03-16 | 2019-09-19 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | Compositions and methods for vaccination against respiratory syncitial virus infection |
| JP2021519596A (ja) | 2018-04-03 | 2021-08-12 | サノフイＳａｎｏｆｉ | フェリチンタンパク質 |
| EP3773703A1 (en) * | 2018-04-03 | 2021-02-17 | Sanofi | Antigenic influenza-ferritin polypeptides |
| CN112512567A (zh) | 2018-04-03 | 2021-03-16 | 赛诺菲 | 抗原性呼吸道合胞病毒多肽 |
| EP3773708A2 (en) | 2018-04-03 | 2021-02-17 | Sanofi | Antigenic epstein barr virus polypeptides |
| EP4227319B1 (en) * | 2018-04-17 | 2025-11-26 | CureVac SE | Novel rsv rna molecules and compositions for vaccination |
| MA52366A (fr) | 2018-04-25 | 2021-03-03 | Prometheus Biosciences Inc | Anticorps anti-tl1a optimisés |
| CN112638411B (zh) | 2018-05-04 | 2025-03-04 | 斯拜生物技术有限公司 | 疫苗组合物 |
| CN110684747B (zh) * | 2018-07-06 | 2024-05-24 | 厦门大学 | 灭活及保存呼吸道合胞病毒的方法 |
| US20210292395A1 (en) * | 2018-07-31 | 2021-09-23 | Glaxosmithkline Biologicals Sa | Antigen purification method |
| WO2020028902A1 (en) | 2018-08-03 | 2020-02-06 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Nipah virus immunogens and their use |
| US20210283238A1 (en) | 2018-08-07 | 2021-09-16 | Glaxosmithkline Biologicals Sa | Novel processes and vaccines |
| PH12021550974A1 (en) * | 2018-11-13 | 2022-05-02 | Janssen Vaccines & Prevention Bv | Stablized pre-fusion rsv f proteins |
| CN113646330A (zh) * | 2018-11-14 | 2021-11-12 | 鲁比克治疗股份有限公司 | 工程化cd25多肽及其用途 |
| US11351242B1 (en) | 2019-02-12 | 2022-06-07 | Modernatx, Inc. | HMPV/hPIV3 mRNA vaccine composition |
| KR102679227B1 (ko) | 2019-02-28 | 2024-06-28 | 케이엠 바이올로직스 가부시키가이샤 | Rsv f/g 키메라 백신 |
| CA3142300C (en) | 2019-06-05 | 2025-02-04 | Glaxosmithkline Biologicals Sa | SAPONIN PURIFICATION |
| US20220306697A1 (en) | 2019-09-04 | 2022-09-29 | University Of Washington | Self-Assembling Protein Nanostructures Displaying Paramyxovirus and/or Pneumovirus F Proteins and Their Use |
| JP7504992B2 (ja) | 2019-10-24 | 2024-06-24 | プロメテウス バイオサイエンシーズ，インク． | Ｔｎｆ様リガンド１ａ（ｔｌ１ａ）に対するヒト化抗体およびその使用 |
| CA3164343A1 (en) | 2019-12-11 | 2021-06-17 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Mumps and measles virus immunogens and their use |
| PH12022551543A1 (en) * | 2019-12-23 | 2023-04-24 | Mitsubishi Tanabe Pharma Corp | Mutant rsv f protein and use thereof |
| US10953089B1 (en) | 2020-01-27 | 2021-03-23 | Novavax, Inc. | Coronavirus vaccine formulations |
| EP4096683A4 (en) * | 2020-01-30 | 2024-04-10 | ModernaTX, Inc. | IMMUNIZATION COMPOSITIONS FOR RESPIRATORY VIRUSES |
| US12194089B2 (en) | 2020-02-04 | 2025-01-14 | CureVac SE | Coronavirus vaccine |
| WO2021222639A2 (en) * | 2020-04-29 | 2021-11-04 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Recombinant human metapneumovirus f proteins and their use |
| US20230242594A1 (en) * | 2020-05-29 | 2023-08-03 | Board Of Regents, The University Of Texas System | Engineered coronavirus spike (s) protein and methods of use thereof |
| MX2022015132A (es) | 2020-05-29 | 2023-03-08 | CureVac SE | Vacunas combinadas a base de acidos nucleicos. |
| WO2021249009A1 (en) * | 2020-06-10 | 2021-12-16 | Sichuan Clover Biopharmaceuticals, Inc. | Rsv vaccine compositions, methods, and uses thereof |
| JP2022023813A (ja) | 2020-07-27 | 2022-02-08 | ファイザー・インク | 組換え生産されたｒｓｖタンパク質の精製方法における陰イオン交換クロマトグラフィー用洗浄溶液の改良 |
| JP2022023814A (ja) | 2020-07-27 | 2022-02-08 | ファイザー・インク | 組換え生産された三量体型のｒｓｖタンパク質の精製方法 |
| CN112226444B (zh) * | 2020-08-25 | 2022-11-04 | 北京交通大学 | 呼吸道合胞病毒全长融合前融合糖蛋白核苷酸序列、重组腺病毒载体及其应用产品 |
| JP2022060169A (ja) | 2020-10-02 | 2022-04-14 | ファイザー・インク | Ｒｓｖ ｆタンパク質生産のための細胞培養工程 |
| IL320367A (en) | 2020-10-09 | 2025-06-01 | Univ Texas | Prefusion-stabilized hmpv f proteins |
| EP4237085A1 (en) | 2020-10-28 | 2023-09-06 | Sanofi Pasteur | Liposomes containing tlr4 agonist, preparation and uses thereof |
| CN112592928B (zh) * | 2020-12-31 | 2021-08-31 | 北京鼎成肽源生物技术有限公司 | 冠状病毒的融合基因、融合蛋白、重组载体、通用型dc疫苗及其制备方法 |
| WO2022175477A1 (en) * | 2021-02-19 | 2022-08-25 | Janssen Vaccines & Prevention B.V. | Stabilized pre-fusion rsv fb antigens |
| BR112023020237A2 (pt) | 2021-04-02 | 2023-12-19 | Bureau D?Etudes Biologiques Scient Et Medicales | Composição imunogênica e processo para preparar a mesma, estrutura metal-orgânica e uso da mesma |
| US12304929B2 (en) * | 2021-04-12 | 2025-05-20 | Sk Bioscience Co., Ltd. | Recombinant RSV live vaccine strain and the preparing method thereof |
| EP4323383A4 (en) * | 2021-04-15 | 2025-08-13 | Merck Sharp & Dohme Llc | ROTAVIRUS VECTORS FOR HETEROLOGOUS GENE DELIVERY |
| EP4384535A4 (en) * | 2021-08-10 | 2025-06-25 | Icosavax, Inc. | Virus-like particle vaccine for respiratory syncytial virus |
| US20250127872A1 (en) * | 2021-09-29 | 2025-04-24 | Sk Bioscience Co., Ltd. | Recombinant live attenuated rsv vaccine strain and production method therefor |
| CN118434756A (zh) * | 2021-11-19 | 2024-08-02 | 达冕生物有限公司 | 核糖核酸呼吸道合胞病毒（rsv）疫苗的组合物和方法 |
| KR102785012B1 (ko) * | 2021-12-14 | 2025-03-20 | 경희대학교 산학협력단 | Rsv 항원 단백질을 포함하는 바이러스 유사입자 및 이를 이용한 백신 |
| CN117715923A (zh) * | 2022-04-29 | 2024-03-15 | 北京新合睿恩生物医疗科技有限公司 | Rsv f蛋白突变体及其应用 |
| WO2023234300A1 (en) * | 2022-05-31 | 2023-12-07 | Vlp Therapeutics Japan, Inc. | Modified vaccine design developments |
| WO2023237649A1 (en) * | 2022-06-10 | 2023-12-14 | Glaxosmithkline Biologicals Sa | Rsv vaccination with trimeric rsv f fusion protein |
| WO2024041773A1 (en) * | 2022-08-22 | 2024-02-29 | Glaxosmithkline Biologicals Sa | Rsv-f proteins |
| JP2025532724A (ja) | 2022-09-29 | 2025-10-03 | ファイザー・インク | Ｒｓｖ ｆタンパク質三量体を含む免疫原性組成物 |
| CN116478296B (zh) * | 2022-10-17 | 2024-02-23 | 厦门大学 | 截短的呼吸道合胞病毒f蛋白及其用途 |
| EP4608440A1 (en) | 2022-10-27 | 2025-09-03 | Pfizer Inc. | Rna molecules encoding rsv-f and vaccines containing them |
| WO2024089634A1 (en) | 2022-10-27 | 2024-05-02 | Pfizer Inc. | Immunogenic compositions against influenza and rsv |
| CN120152987A (zh) * | 2022-11-04 | 2025-06-13 | 赛诺菲巴斯德有限公司 | 呼吸道合胞病毒rna疫苗接种 |
| EP4615980A1 (en) * | 2022-11-09 | 2025-09-17 | Nykode Therapeutics ASA | Co-expression of constructs and polypeptides |
| KR102531775B1 (ko) | 2022-11-11 | 2023-05-15 | 대한민국 | Rsv f 항체 또는 이의 항원 결합 단편 |
| CN116284266B (zh) * | 2022-11-21 | 2024-01-19 | 怡道生物科技(苏州)有限公司 | 突变型呼吸道合胞病毒融合前f蛋白及其应用 |
| WO2024115561A1 (en) * | 2022-12-01 | 2024-06-06 | Glaxosmithkline Biologicals Sa | Vaccination against rsv |
| EP4630049A1 (en) | 2022-12-11 | 2025-10-15 | Pfizer Inc. | Immunogenic compositions against influenza and rsv |
| CN120659803A (zh) * | 2023-01-17 | 2025-09-16 | 斯克里普斯研究学院 | 工程化副黏病毒可溶性融合（f）蛋白及相关疫苗 |
| PE20252308A1 (es) | 2023-01-18 | 2025-09-22 | Pfizer | Vacunas contra enfermedades respiratorias |
| WO2024163092A1 (en) * | 2023-02-03 | 2024-08-08 | Vernagen, LLC | Respiratory syncytial virus mrna vaccine |
| WO2024164020A2 (en) * | 2023-02-03 | 2024-08-08 | The Trustees Of Columbia University In The City Of New York | Methods of inhibiting paramyxoviridae fusion to a target cell |
| IL322806A (en) * | 2023-02-21 | 2025-10-01 | Msd Int Business Gmbh | Stabilized trimeric fusion proteins of RSV without a heterologous trimerization domain |
| WO2024175040A1 (en) * | 2023-02-22 | 2024-08-29 | Everest Medicines (China) Co., Ltd. | RSV mRNA VACCINES |
| WO2024193380A1 (zh) * | 2023-03-17 | 2024-09-26 | 成都威斯克生物医药有限公司 | 抗呼吸道合胞病毒感染的疫苗 |
| CN116536357A (zh) * | 2023-04-17 | 2023-08-04 | 中国医学科学院输血研究所 | 构建CRISPR/Cas12a中sgRNA剪切活性筛选系统的方法 |
| CN118108812B (zh) * | 2023-05-04 | 2025-04-15 | 国药中生生物技术研究院有限公司 | Rsv f蛋白的突变体 |
| CN118994329A (zh) * | 2023-05-18 | 2024-11-22 | 北京微星生物科技有限公司 | 融合前rsv f蛋白及其应用 |
| WO2024241172A2 (en) | 2023-05-19 | 2024-11-28 | Glaxosmithkline Biologicals Sa | Methods for eliciting an immune response to respiratory syncycial virus and streptococcus pneumoniae infection |
| CN118994328B (zh) * | 2023-05-19 | 2025-07-08 | 珠海丽凡达生物技术有限公司 | 呼吸道合胞病毒疫苗及其制备方法和应用 |
| CN119019514A (zh) * | 2023-05-25 | 2024-11-26 | 江苏瑞科生物技术股份有限公司 | 一种具有免疫原性的呼吸道合胞病毒（rsv）多肽 |
| WO2024251281A1 (zh) * | 2023-06-07 | 2024-12-12 | 四川三叶草生物制药有限公司 | Rsv疫苗组合物、方法及其用途 |
| AR132981A1 (es) * | 2023-06-16 | 2025-08-13 | Glaxosmithkline Biologicals Sa | Proteínas rsv-f sustituidas con cisteína |
| WO2025012756A1 (en) | 2023-07-07 | 2025-01-16 | Pfizer Inc. | Amphiphilic tlr7/8 adjuvants and uses thereof |
| CN119431524A (zh) * | 2023-08-07 | 2025-02-14 | 北京新合睿恩生物医疗科技有限公司 | Rsv融合前构象f蛋白的突变体及其应用 |
| WO2025092933A1 (zh) * | 2023-10-31 | 2025-05-08 | 上海蓝鹊生物医药有限公司 | 一种rsv抗原、核酸、重组表达载体、药物组合物及其应用 |
| CN120022355A (zh) * | 2023-11-22 | 2025-05-23 | 长春百克生物科技股份公司 | 一种mRNA疫苗及其应用 |
| CN117304278B (zh) * | 2023-11-28 | 2024-04-16 | 江苏瑞科生物技术股份有限公司 | 一种重组rsv f蛋白及其应用 |
| WO2025126071A1 (en) | 2023-12-14 | 2025-06-19 | Pfizer Inc. | Rna molecules |
| KR20250094574A (ko) * | 2023-12-15 | 2025-06-25 | 에스케이바이오사이언스(주) | 변이 rsv 단백질 |
| KR102816014B1 (ko) * | 2023-12-20 | 2025-06-02 | 에스케이바이오사이언스(주) | Rsv 의 가용성 f 단백질을 생성하기 위한 재조합 전구체 폴리펩티드 및 이의 이용 |
| CN117586425B (zh) * | 2024-01-19 | 2024-06-14 | 北京安百胜生物科技有限公司 | 一种重组呼吸道合胞病毒颗粒抗原其制备方法和应用 |
| CN117567652B (zh) * | 2024-01-19 | 2024-05-14 | 北京安百胜生物科技有限公司 | 一种重组呼吸道合胞病毒颗粒抗原 |
| CN117586357B (zh) * | 2024-01-19 | 2024-07-09 | 北京安百胜生物科技有限公司 | 一种具有免疫原性的呼吸道合胞病毒（rsv）多肽 |
| CN117586359A (zh) * | 2024-01-19 | 2024-02-23 | 北京安百胜生物科技有限公司 | 一种具有免疫原性的呼吸道合胞病毒（rsv）多肽 |
| CN117645655B (zh) * | 2024-01-26 | 2024-05-24 | 普大生物科技(泰州)有限公司 | 一种肺炎球菌多糖-rsv重组蛋白结合疫苗及其制备方法 |
| WO2025163460A2 (en) | 2024-01-30 | 2025-08-07 | Pfizer Inc. | Vaccines against respiratory diseases |
| WO2025186719A1 (en) | 2024-03-06 | 2025-09-12 | Pfizer Inc. | Immunogenic compositions and uses thereof |
| CN118440937B (zh) * | 2024-04-09 | 2025-02-25 | 嘉译生物医药(杭州)有限公司 | 新型的人合胞病毒RSV B mRNA疫苗 |
| CN118580323B (zh) * | 2024-05-22 | 2025-06-17 | 苏州聚微生物科技有限公司 | Rsv融合前f蛋白的突变体及其制备和应用 |
| CN118496324B (zh) * | 2024-05-22 | 2025-10-21 | 苏州聚微生物科技有限公司 | RSV pre-F突变体及其生产方法和用途 |
| CN118406159B (zh) * | 2024-05-22 | 2025-07-08 | 苏州聚微生物科技有限公司 | RSV pre-F截短体及其生产方法和应用 |
| CN119074910A (zh) * | 2024-08-30 | 2024-12-06 | 中国医学科学院病原生物学研究所 | 以麻疹减毒活疫苗为载体的重组呼吸道合胞病毒疫苗及其制备方法 |
| CN119176859B (zh) * | 2024-11-26 | 2025-03-14 | 北京成大天和生物科技有限公司 | 呼吸道合胞病毒f蛋白突变体及其应用 |
| CN120248057B (zh) * | 2024-12-26 | 2025-12-02 | 北京华诺泰生物医药科技有限公司 | 一种呼吸道合胞病毒f蛋白突变体及其应用 |
Family Cites Families (109)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US472209A (en) | 1892-04-05 | Vacuum-pan | ||
| US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
| US4235877A (en) | 1979-06-27 | 1980-11-25 | Merck & Co., Inc. | Liposome particle containing viral or bacterial antigenic subunit |
| US4372945A (en) | 1979-11-13 | 1983-02-08 | Likhite Vilas V | Antigen compounds |
| US4675189A (en) | 1980-11-18 | 1987-06-23 | Syntex (U.S.A.) Inc. | Microencapsulation of water soluble active polypeptides |
| IL61904A (en) | 1981-01-13 | 1985-07-31 | Yeda Res & Dev | Synthetic vaccine against influenza virus infections comprising a synthetic peptide and process for producing same |
| US4722848A (en) | 1982-12-08 | 1988-02-02 | Health Research, Incorporated | Method for immunizing animals with synthetically modified vaccinia virus |
| US4436727A (en) | 1982-05-26 | 1984-03-13 | Ribi Immunochem Research, Inc. | Refined detoxified endotoxin product |
| US4866034A (en) | 1982-05-26 | 1989-09-12 | Ribi Immunochem Research Inc. | Refined detoxified endotoxin |
| SE8205892D0 (sv) | 1982-10-18 | 1982-10-18 | Bror Morein | Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin |
| US4501728A (en) | 1983-01-06 | 1985-02-26 | Technology Unlimited, Inc. | Masking of liposomes from RES recognition |
| JPS60100516A (ja) | 1983-11-04 | 1985-06-04 | Takeda Chem Ind Ltd | 徐放型マイクロカプセルの製造法 |
| US4957735A (en) | 1984-06-12 | 1990-09-18 | The University Of Tennessee Research Corporation | Target-sensitive immunoliposomes- preparation and characterization |
| CA1256638A (en) | 1984-07-06 | 1989-06-27 | Motoaki Tanaka | Polymer and its production |
| US5019369A (en) | 1984-10-22 | 1991-05-28 | Vestar, Inc. | Method of targeting tumors in humans |
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| JP2551756B2 (ja) | 1985-05-07 | 1996-11-06 | 武田薬品工業株式会社 | ポリオキシカルボン酸エステルおよびその製造法 |
| US4707543A (en) | 1985-09-17 | 1987-11-17 | The United States Of America As Represented By The Secretary Of The Army | Process for the preparation of detoxified polysaccharide-outer membrane protein complexes, and their use as antibacterial vaccines |
| US5091309A (en) | 1986-01-16 | 1992-02-25 | Washington University | Sindbis virus vectors |
| US4877611A (en) | 1986-04-15 | 1989-10-31 | Ribi Immunochem Research Inc. | Vaccine containing tumor antigens and adjuvants |
| US4902505A (en) | 1986-07-30 | 1990-02-20 | Alkermes | Chimeric peptides for neuropeptide delivery through the blood-brain barrier |
| US4837028A (en) | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US5057540A (en) | 1987-05-29 | 1991-10-15 | Cambridge Biotech Corporation | Saponin adjuvant |
| CA1331443C (en) | 1987-05-29 | 1994-08-16 | Charlotte A. Kensil | Saponin adjuvant |
| US5726292A (en) | 1987-06-23 | 1998-03-10 | Lowell; George H. | Immuno-potentiating systems for preparation of immunogenic materials |
| US5004697A (en) | 1987-08-17 | 1991-04-02 | Univ. Of Ca | Cationized antibodies for delivery through the blood-brain barrier |
| US5278302A (en) | 1988-05-26 | 1994-01-11 | University Patents, Inc. | Polynucleotide phosphorodithioates |
| US4912094B1 (en) | 1988-06-29 | 1994-02-15 | Ribi Immunochem Research Inc. | Modified lipopolysaccharides and process of preparation |
| CA1336955C (en) * | 1988-09-20 | 1995-09-12 | Peter R. Paradiso | Respiratory syncytial virus: vaccines and diagnostic assays |
| US5217879A (en) | 1989-01-12 | 1993-06-08 | Washington University | Infectious Sindbis virus vectors |
| US5055303A (en) | 1989-01-31 | 1991-10-08 | Kv Pharmaceutical Company | Solid controlled release bioadherent emulsions |
| US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| US5271961A (en) | 1989-11-06 | 1993-12-21 | Alkermes Controlled Therapeutics, Inc. | Method for producing protein microspheres |
| US5188837A (en) | 1989-11-13 | 1993-02-23 | Nova Pharmaceutical Corporation | Lipsopheres for controlled delivery of substances |
| US5268164A (en) | 1990-04-23 | 1993-12-07 | Alkermes, Inc. | Increasing blood-brain barrier permeability with permeabilizer peptides |
| US5254342A (en) | 1991-09-30 | 1993-10-19 | University Of Southern California | Compositions and methods for enhanced transepithelial and transendothelial transport or active agents |
| US5643578A (en) | 1992-03-23 | 1997-07-01 | University Of Massachusetts Medical Center | Immunization by inoculation of DNA transcription unit |
| AU668384B2 (en) | 1992-03-12 | 1996-05-02 | Alkermes Controlled Therapeutics, Inc. | Controlled release ACTH containing microspheres |
| US5534496A (en) | 1992-07-07 | 1996-07-09 | University Of Southern California | Methods and compositions to enhance epithelial drug transport |
| CA2142007C (en) | 1992-08-11 | 2007-10-30 | Robert Glen Urban | Immunomodulatory peptides |
| US5593972A (en) | 1993-01-26 | 1997-01-14 | The Wistar Institute | Genetic immunization |
| ES2162139T5 (es) | 1993-03-23 | 2008-05-16 | Smithkline Beecham Biologicals S.A. | Composiciones de vacuna que contienen monofosforil-lipido a 3-o-desacilado. |
| FR2705686B1 (fr) | 1993-05-28 | 1995-08-18 | Transgene Sa | Nouveaux adénovirus défectifs et lignées de complémentation correspondantes. |
| ES2310924T3 (es) | 1993-07-13 | 2009-01-16 | Centelion | Vectores adenovirales defectivos y utilizacion en terapia genica. |
| US5514670A (en) | 1993-08-13 | 1996-05-07 | Pharmos Corporation | Submicron emulsions for delivery of peptides |
| US5961970A (en) | 1993-10-29 | 1999-10-05 | Pharmos Corporation | Submicron emulsions as vaccine adjuvants |
| CN1055093C (zh) | 1993-11-17 | 2000-08-02 | 实验室奥姆公司 | 葡糖胺二糖类、其制备方法和用途、以及含有这些二糖的药物组合物 |
| WO1995016772A1 (en) | 1993-12-14 | 1995-06-22 | Cornell Research Foundation, Inc. | Adenovirus gene expression system |
| WO1995026204A1 (en) | 1994-03-25 | 1995-10-05 | Isis Pharmaceuticals, Inc. | Immune stimulation by phosphorothioate oligonucleotide analogs |
| US5851806A (en) | 1994-06-10 | 1998-12-22 | Genvec, Inc. | Complementary adenoviral systems and cell lines |
| WO1995034671A1 (en) | 1994-06-10 | 1995-12-21 | Genvec, Inc. | Complementary adenoviral vector systems and cell lines |
| EP0772619B2 (en) | 1994-07-15 | 2010-12-08 | The University of Iowa Research Foundation | Immunomodulatory oligonucleotides |
| AUPM873294A0 (en) | 1994-10-12 | 1994-11-03 | Csl Limited | Saponin preparations and use thereof in iscoms |
| IL116816A (en) | 1995-01-20 | 2003-05-29 | Rhone Poulenc Rorer Sa | Cell for the production of a defective recombinant adenovirus or an adeno-associated virus and the various uses thereof |
| UA56132C2 (uk) | 1995-04-25 | 2003-05-15 | Смітклайн Бічем Байолоджікалс С.А. | Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини |
| US5837511A (en) | 1995-10-02 | 1998-11-17 | Cornell Research Foundation, Inc. | Non-group C adenoviral vectors |
| US5666153A (en) | 1995-10-03 | 1997-09-09 | Virtual Shopping, Inc. | Retractable teleconferencing apparatus |
| US6020182A (en) | 1996-07-12 | 2000-02-01 | Connaught Laboratories Limited | Subunit respiratory syncytial virus vaccine preparation |
| US5856462A (en) | 1996-09-10 | 1999-01-05 | Hybridon Incorporated | Oligonucleotides having modified CpG dinucleosides |
| US6303347B1 (en) | 1997-05-08 | 2001-10-16 | Corixa Corporation | Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors |
| US6764840B2 (en) | 1997-05-08 | 2004-07-20 | Corixa Corporation | Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors |
| US6113918A (en) | 1997-05-08 | 2000-09-05 | Ribi Immunochem Research, Inc. | Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors |
| GB9727262D0 (en) | 1997-12-24 | 1998-02-25 | Smithkline Beecham Biolog | Vaccine |
| CA2293694A1 (en) * | 1998-06-10 | 1999-12-16 | Incyte Pharmaceuticals, Inc. | New carboxypeptidase inhibitor |
| US6113913A (en) | 1998-06-26 | 2000-09-05 | Genvec, Inc. | Recombinant adenovirus |
| US6551600B2 (en) | 1999-02-01 | 2003-04-22 | Eisai Co., Ltd. | Immunological adjuvant compounds compositions and methods of use thereof |
| US20040006242A1 (en) | 1999-02-01 | 2004-01-08 | Hawkins Lynn D. | Immunomodulatory compounds and method of use thereof |
| AU1581400A (en) | 1999-12-22 | 2001-07-03 | Om Pharma | Acyl pseudopeptides bearing a functionalised auxiliary spacer |
| US6764685B1 (en) | 2000-03-21 | 2004-07-20 | Medimmune Vaccines, Inc. | Recombinant parainfluenza virus expression systems and vaccines |
| KR100787073B1 (ko) | 2000-06-28 | 2007-12-21 | 글리코파이, 인크. | 변형된 당단백질의 제조방법 |
| US20030232061A1 (en) | 2001-10-18 | 2003-12-18 | Fouchier Ronaldus Adrianus Maria | Recombinant parainfluenza virus expression systems and vaccines comprising heterologous antigens derived from metapneumovirus |
| ATE489968T1 (de) | 2001-03-09 | 2010-12-15 | Id Biomedical Corp Quebec | Proteosom-liposaccharid-vakzine-adjuvans |
| KR100892614B1 (ko) | 2001-04-17 | 2009-04-09 | 다이닛본 스미토모 세이야꾸 가부시끼가이샤 | 신규 아데닌 유도체 |
| EP1425045A4 (en) | 2001-09-13 | 2004-11-10 | Genvec Inc | ADENOVIRAL VECTOR AND RELEVANT SYSTEM AND METHOD FOR THE PRODUCTION AND USE THEREOF |
| US7041489B2 (en) | 2001-10-01 | 2006-05-09 | The Uab Research Foundation | Recombinant respiratory syncytial viruses with deleted surface glycoprotein genes and uses thereof |
| AU2002343728A1 (en) | 2001-11-16 | 2003-06-10 | 3M Innovative Properties Company | Methods and compositions related to irm compounds and toll-like receptor pathways |
| CA2477235A1 (en) | 2002-02-21 | 2003-09-04 | Medimmune Vaccines, Inc. | Recombinant parainfluenza virus expression systems and vaccines comprising heterologous antigens derived from metapneumovirus |
| CA2494485A1 (en) | 2002-07-25 | 2004-02-05 | Medimmune, Inc. | Methods of treating and preventing rsv, hmpv, and piv using anti-rsv, anti-hmpv, and anti-piv antibodies |
| KR20050073559A (ko) | 2002-10-16 | 2005-07-14 | 더 스크립스 리서치 인스티튜트 | 당단백질 합성 |
| JP2006517974A (ja) | 2003-02-13 | 2006-08-03 | スリーエム イノベイティブ プロパティズ カンパニー | Ｉｒｍ化合物およびトル様受容体８に関する方法および組成物 |
| CA2523657A1 (en) | 2003-04-25 | 2005-03-31 | Medimmune Vaccines, Inc. | Recombinant parainfluenza virus expression systems and vaccines comprising heterologous antigens derived from metapneumovirus |
| JP2007525178A (ja) | 2003-04-25 | 2007-09-06 | メッドイミューン バクシーンズ，インコーポレイティド | メタニューモウイルス株、そのワクチン製剤における用途、抗原性配列の発現のためのベクターとしての用途、並びにウイルス増殖方法 |
| WO2005111621A2 (en) | 2004-04-16 | 2005-11-24 | Uab Research Foundation | Molecular scaffolds for hiv-1 epitopes |
| US8647818B2 (en) | 2005-02-18 | 2014-02-11 | UAB Research Foundation, University of Alabama—Birmingham | Molecular scaffolds for HIV-1 immunogens |
| US20060216700A1 (en) | 2005-03-10 | 2006-09-28 | Medimmune Vaccines, Inc. | Metapneumovirus strains and their use in vaccine formulations and as vectors for expression of antigenic sequences and methods for propagating virus |
| US7728106B2 (en) | 2005-07-01 | 2010-06-01 | University Of Maryland Biotechnology Institute | HIV-1 glycopeptides and derivatives; preparation and applications thereof |
| CA2647632C (en) | 2006-03-27 | 2017-06-27 | University Of Maryland Biotechnology Institute | Glycoprotein synthesis and remodeling by enzymatic transglycosylation |
| WO2008025015A2 (en) | 2006-08-25 | 2008-02-28 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Epitope-protein scaffolds and their use |
| EP1997830A1 (en) | 2007-06-01 | 2008-12-03 | AIMM Therapeutics B.V. | RSV specific binding molecules and means for producing them |
| EP2069485A4 (en) | 2007-07-13 | 2011-05-25 | Medimmune Llc | PREPARATION OF NEGATIVE STRAND RNA VIRUSES BY ELECTROPORATION |
| WO2009079796A1 (en) * | 2007-12-24 | 2009-07-02 | Id Biomedical Corporation Of Quebec | Recombinant rsv antigens |
| EP4186978A1 (en) | 2007-12-27 | 2023-05-31 | Universität Zürich | Replication-defective arenavirus vectors |
| US20110318376A1 (en) * | 2008-12-24 | 2011-12-29 | University Of Rochester | Recombinant expression of self-folding neutralizing epitope-bearing subdomains of the respiratory syncytial virus attachment and fusion proteins |
| KR20120026526A (ko) | 2009-05-12 | 2012-03-19 | 트랜스진 에스.에이. | 불멸화 조류 세포주 및 그의 용도 |
| WO2010149743A2 (en) * | 2009-06-24 | 2010-12-29 | Id Biomedical Corporation Of Quebec | Vaccine |
| AU2010264688A1 (en) | 2009-06-24 | 2012-01-19 | Glaxosmithkline Biologicals S.A. | Recombinant RSV antigens |
| SI3178490T1 (sl) * | 2009-07-15 | 2022-08-31 | Glaxosmithkline Biologicals S.A. | Sestavki proteina F RSV-ja in postopki za pripravo le-teh |
| CA2776249C (en) | 2009-10-06 | 2021-01-19 | Medimmune Ltd | Rsv-specific binding molecule |
| US8568726B2 (en) | 2009-10-06 | 2013-10-29 | Medimmune Limited | RSV specific binding molecule |
| WO2011050168A2 (en) | 2009-10-21 | 2011-04-28 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Servic | Rsv immunogens, antibodies and compositions thereof |
| SI3275892T1 (sl) * | 2011-05-13 | 2020-06-30 | Glaxosmithkline Biologicals S.A. | Prefuzijski RSV F antigeni |
| CN102210860B (zh) | 2011-05-31 | 2012-11-21 | 昆明理工大学 | 一种结核分枝杆菌tb10．4-f1融合蛋白疫苗及制备方法 |
| ES2395677B1 (es) * | 2011-07-29 | 2013-12-26 | Instituto De Salud Carlos Iii | Proteína F del VRSH en conformación pre-fusión estabilizada y anticuerpos neutralizantes específicos frente a la misma. |
| JP2015525794A (ja) | 2012-08-06 | 2015-09-07 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | 乳児においてｒｓｖ及び百日咳菌に対する免疫応答を惹起するための方法 |
| BR112015011389A2 (pt) | 2012-11-20 | 2017-08-22 | Glaxosmithkline Biologicals Sa | Complexo f do vírus sincicial respiratório, métodos para produzir um complexo f do vírus sincicial respiratório e para indução de uma resposta imunológica a um f de rsv em um indivíduo, e, composição imunogênica |
| US9738689B2 (en) | 2013-03-13 | 2017-08-22 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Prefusion RSV F proteins and their use |
| SMT202400297T1 (it) * | 2013-03-13 | 2024-09-16 | The United States Of America As Represented By The Secretary Department Of Health And Human Services | Proteine f del rsv pre-fusione e loro uso |
| EP2975052B1 (en) | 2013-03-15 | 2020-09-23 | Xiamen University | Epitope of rsv fusion protein and antibody identifying same |
| SG11201508567XA (en) | 2013-04-25 | 2015-11-27 | Crucell Holland Bv | Stabilized soluble prefusion rsv f polypeptides |
-
2014
- 2014-03-13 SM SM20240297T patent/SMT202400297T1/it unknown
- 2014-03-13 PL PL14775224.0T patent/PL2970398T3/pl unknown
- 2014-03-13 HU HUE14775224A patent/HUE067333T2/hu unknown
- 2014-03-13 SI SI201432090T patent/SI2970398T1/sl unknown
- 2014-03-13 CN CN201480027499.3A patent/CN105473604B/zh active Active
- 2014-03-13 HR HRP20240996TT patent/HRP20240996T1/hr unknown
- 2014-03-13 KR KR1020227033808A patent/KR102766946B1/ko active Active
- 2014-03-13 US US14/776,651 patent/US10017543B2/en active Active
- 2014-03-13 KR KR1020257003905A patent/KR20250023601A/ko active Pending
- 2014-03-13 FI FIEP14775224.0T patent/FI2970398T3/fi active
- 2014-03-13 MX MX2015013065A patent/MX385818B/es unknown
- 2014-03-13 LT LTEPPCT/US2014/026714T patent/LT2970398T/lt unknown
- 2014-03-13 EP EP24174501.7A patent/EP4421177A3/en active Pending
- 2014-03-13 RS RS20240825A patent/RS65760B1/sr unknown
- 2014-03-13 PT PT147752240T patent/PT2970398T/pt unknown
- 2014-03-13 EP EP14775224.0A patent/EP2970398B1/en active Active
- 2014-03-13 WO PCT/US2014/026714 patent/WO2014160463A1/en not_active Ceased
- 2014-03-13 CN CN202110068562.XA patent/CN112851766A/zh active Pending
- 2014-03-13 DK DK14775224.0T patent/DK2970398T3/da active
- 2014-03-13 AU AU2014243756A patent/AU2014243756B2/en active Active
- 2014-03-13 CA CA2902877A patent/CA2902877A1/en active Pending
- 2014-03-13 ES ES14775224T patent/ES2981623T3/es active Active
- 2014-03-13 RU RU2015142981A patent/RU2761631C2/ru active
- 2014-03-13 KR KR1020157025199A patent/KR102450375B1/ko active Active
- 2014-03-13 JP JP2016502221A patent/JP6703475B2/ja active Active
-
2015
- 2015-09-11 MX MX2021010519A patent/MX2021010519A/es unknown
-
2018
- 2018-07-02 US US16/025,858 patent/US11130785B2/en active Active
- 2018-12-21 AU AU2018282476A patent/AU2018282476B2/en active Active
-
2020
- 2020-02-12 JP JP2020021468A patent/JP7043530B2/ja active Active
-
2021
- 2021-03-08 AU AU2021201468A patent/AU2021201468B2/en active Active
- 2021-09-17 US US17/478,533 patent/US20220002351A1/en not_active Abandoned
-
2022
- 2022-03-16 JP JP2022041006A patent/JP7503588B2/ja active Active
-
2023
- 2023-02-09 AU AU2023200712A patent/AU2023200712B2/en active Active
- 2023-09-11 US US18/464,786 patent/US11981707B2/en active Active
-
2024
- 2024-06-10 JP JP2024093392A patent/JP2024107243A/ja active Pending
- 2024-12-30 US US19/005,704 patent/US20250368690A1/en active Pending
-
2025
- 2025-05-19 AU AU2025203614A patent/AU2025203614A1/en active Pending